



→ Calla Simeone

Associate

2099 Pennsylvania Avenue, N.W.
Suite 100
Washington, DC 20006-6801

T: +1.202.747.2647

F: +1.202.747.3920

csimeone@sheppardmullin.com

Calla Simeone is an associate in the Business Trial Practice Group in the firm's Washington, D.C. office and a member of the firm's Healthcare Team.

Areas of Practice

Calla represents individuals and corporations in complex commercial litigation and government investigations. A substantial portion of Calla's practice is devoted to representing healthcare clients, including hospitals and health systems, managed care organizations, and physician and specialty practice groups. She has experience defending these clients in commercial disputes and litigation and government investigations involving allegations under the False Claims Act, Anti-Kickback Statute, and similar anti-fraud statutes. She also assists companies in conducting internal investigations regarding allegations of fraud and developing cost-effective and practical compliance programs.

Calla is a member of the firm's Women in Healthcare Leadership Collaborative, whose goal is to promote the advancement of women in the healthcare industry.

Calla also maintains an active pro bono practice. She is currently part of a team advocating for the expansion and full implementation of alternate emergency response systems, such as peer support teams, to respond to people in mental health crises.

Calla received her M.Sc. in International Health Policy from the London School of Economics, where she wrote her dissertation on the role of public-private partnerships in drug development. She received her J.D. from Georgetown University Law Center, where she worked as a student attorney in Georgetown's Health Justice Alliance Legal Clinic, a medical-legal partnership, representing clients in D.C. Superior Court.

Articles

- Access to Abortion Pill on the Precipice
Chicago Medicine Magazine, 07.2023

Government Contracts & Investigations Blog Posts

- "The Expanding Scope of FCA-Cybersecurity Liability," September 5, 2025

Healthcare Law Blog Posts

- "Regeneron, the False Claims Act, and a New Era in Government Enforcement," October 30, 2025

- "Texas Court Stays CMS CY2025 Final Rule on Agent and Broker Compensation and Contract Term Restrictions," July 5, 2024
- "Supreme Court Unanimously Preserves Access to Mifepristone," June 14, 2024
- "Increased Scrutiny into Agents & Brokers in the Medicare Advantage Space," April 15, 2024
- "Fifth Circuit Rules to Reinstate Abortion Pill Restrictions," August 17, 2023
- "Access to Abortion Pill on the Precipice: A Deep Dive into the Federal Court Rulings that will Decide the Fate of Mifepristone," June 15, 2023
- "Access to Abortion Pill in Limbo: Navigating the Intricacies of Conflicting Federal Court Rulings in Texas and Washington State," April 14, 2023

Media Mentions

MAOs, Brokers, Agents Get Relief with Legal Pause on Policy Changes
AIS Health, 07.19.2024

Sheppard Mullin Bolsters Fight to Mend DC Police's Mental Health Response
National Law Journal, 07.07.2023

Practices

False Claims Act

Healthcare

Litigation

Women in Healthcare Leadership Collaborative

Industries

Healthcare

Telecom

Education

J.D., Georgetown University Law Center, 2021

M.Sc., International Health Policy, London School of Economics, 2018

B.A., George Washington University, 2016

Admissions

District of Columbia

Massachusetts